Zycortal® (Dechra Veterinary Products) is indicated for replacement therapy for mineralocorticoid deficiency in dogs with primary hypoadrenocorticism. Zycortal contains desoxycortone pivalate (DOCP) – an aldosterone analogue with purely mineralocorticoid effect. Zycortal is available as a prolonged-release suspension for subcutaneous injection and the dosing interval is approximately 25 days. The exact dose to be given and the interval between treatments depend on the dog’s clinical response as well as sodium and potassium levels. A glucocorticoid (. prednisolone) is also needed daily to replace the missing cortisol. To obtain a Monitoring and Dose Adjustment Flowchart, or for further advice, contact Dechra by e-mailing technical@.
Treatment: If a pancreatic or liver tumor is identified and able to be surgically excised, the skin lesions may normalize for an extended period of time, but because these tumors metastasize (spread to other areas of the body) quickly, surgery is not curative. In cases of end stage liver disease, surgery is not possible, and the goal of therapy is to increase quality of life and decrease uncomfortable skin lesions with supportive care and addressing the nutritional abnormalities. Supportive care includes supplementing protein and necessary minerals and enzymes through the diet and oral supplements or by weekly intravenous amino acid infusions that are performed in the hospital on an outpatient basis until improvement in the skin is noted. Unfortunately, despite the supportive care, the disease will progress.